Please note: This post is not intended for distribution or publication, directly or indirectly, to US persons or in or into the United States, any EEA member state, Australia, Canada, the Republic of South Africa or Japan or any other jurisdiction where it is unlawful to distribute this post.
Today we are delighted to be able to share the news that our forthcoming IPO, the Conviction Life Sciences Company, is now available on many of the UK's key investment platforms. These include:
- AJ Bell: https://www.ajbell.co.uk
- Equiniti: https://eqi.co.uk and https://www.shareview.co.uk
- Hargreaves Lansdown: https://www.hl.co.uk/shares/ipos-and-new-issues/Conviction-Life-Sciences-Company
- Interactive Investor: https://www.ii.co.uk
- Jarvis Investment Management: https://www.sharedealactive.co.uk and https://www.x-o.co.uk
- PrimaryBid: https://primarybid.com/uk
Our sincere thanks to all of you who were kind enough to fill in our launch IPO Survey the other day!
Please do have a look at the "How to Invest" section of our website that has links to all of these platforms and more information about how to invest more generally.
In addition to getting the Company listed on the key platforms, we have been delighted by the coverage the Company has received in the UK press in the last few days. All articles are on the CLSC website if you would like to read more.
I was more than a little honoured to be invited on to the Ian King Live show on Sky News on Friday morning to discuss the Company and the opportunity in life sciences more generally, and our intermediaries offer announcement was covered by the likes of Shares Magazine, Financial News and MarketWatch.
Leading finance journalist, Joanne Hart, who writes the Midas column in the Mail on Sunday was also kind enough to write the following piece in that newspaper on Sunday: "Why life sciences start-up could be a wealth booster - Conviction Life Sciences Company should make the grade".
Investor Presentation Video
The final thing to share today is that last Wednesday I was able to record a video of our investor presentation with Robin Davison, the biotech & healthcare analyst at research company QuotedData. This is now available to view in full on our website along with some questions from Robin.
We now have a couple of big weeks ahead of us with numerous investor meetings between now and closing the IPO on Tuesday the 13th of December.
If you are interested in investing and supporting one of the few investment company IPOs in London this year, please do look up "CLSC" with your investment platform or stockbroker or use the links above.
Andrew Craig is a director of Plain English Finance Limited ("Plain English Finance") which is authorised and regulated by the Financial Conduct Authority (564876) with its registered office at Stag Gates House, 63/64 The Avenue, Southampton, Hampshire SO17 1XS, United Kingdom.
This post, which has been issued by Plain English Finance, is a financial promotion and is not intended to be investment advice. This post is intended for UK residents only.
The purpose of this post is to provide summary information regarding the Company and is for information and discussion purposes only; it should not be considered an offer or solicitation of an offer to buy or sell shares in the capital of the Company. In particular, this post does not constitute an offer to sell, or the solicitation of an offer to acquire or subscribe for shares in the capital of the Company in any jurisdiction where to do so would be unlawful.
This post is an advertisement and does not constitute a prospectus or an offer in respect of any securities and is not intended to provide the basis for any decision in respect of the Company. An investment decision must be made solely on the basis of the prospectus issued by the Company (especially the risk factors set out therein) and which is available on the Company’s website at www.clsc.uk, subject to certain access restrictions.
Plain English Finance does not make any recommendations regarding the suitability of any product for you and the information provided here should not be considered as investment or other advice or a recommendation to buy, sell or hold a particular investment.
To reiterate, investments mentioned herein may not be suitable for you and you must make your own independent assessment and rely on your own judgement (or that of your financial adviser) in order to determine whether any particular investment represents a suitable investment opportunity for you on the basis of your personal circumstances, tax position and available financial resources and the legal, regulatory, tax and investment consequences and risks of investing. If you are in any doubt about the information here or on our or the Company's websites please consult your financial or other professional adviser.
The Company operates under the Companies (Guernsey) Law 2008, as amended, and is not regulated as a collective investment scheme by the Financial Conduct Authority of the United Kingdom. Your capital is at risk with this investment. The value of shares and a return from them is not guaranteed and the share price can fall as well as rise due to stock market movements. When you sell your investment you may get back less than you originally invested. The price of shares in the Company is determined by market supply and demand and may be different to the net asset value of the Company.
Past performance is not a reliable indicator of future results. Forecasts are not a reliable indicator of future performance. Investments in the Company are subject to risks associated with investments in the biotechnology sector. This post may include statements that are, or may be deemed to be, "forward-looking statements". Forward-looking statements are subject to risks and uncertainties and, accordingly, the Company’s actual future financial results and operational performance may differ materially from the results and performance expressed in, or implied by, the statements. These forward-looking statements speak only as at the date of this post and cannot be relied upon as a guide to future performance.
The Ordinary Shares have not been and will not be registered under the United States Securities Act of 1933 (as amended) (the "US Securities Act") or with any securities regulatory authority of any state or other jurisdiction of the United States, and may not be offered or sold within the United States or to, or for the account or benefit of, US Persons (as defined in Regulation S under the US Securities Act ("Regulation S")), except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the US Securities Act and in compliance with any applicable securities laws of any state or other jurisdiction in the United States. In addition, the Company has not been and will not be registered under the United States Investment Company Act of 1940, (as amended) (the "US Investment Company Act"), and recipients of the Prospectus will not be entitled to the benefits of that Act.
This post is not for publication or distribution, directly or indirectly, in or into the United States of America. This post is not an offer of securities for sale into the United States. No public offering of securities is being made in the United States.
The offer and sale of Ordinary Shares has not been and will not be registered under the applicable securities laws of any member state of the EEA, Canada, Japan or the Republic of South Africa. Subject to certain exemptions, the Ordinary Shares may not be offered to or sold within any member state of the EEA, Canada, Japan or the Republic of South Africa or to any national, resident or citizen of any member state of the EEA, Canada, Japan or the Republic of South Africa.